	US 12,213,995 B2
	Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
Kenneth Allen Pettine, Fort Collins, CO (US); and Timothy Alexander Moseley, Fallbrook, CA (US)
Assigned to DIRECT BIOLOGICS, LLC, Austin, TX (US)
Appl. No. 17/628,011
Filed by DIRECT BIOLOGICS, LLC, Austin, TX (US)
PCT Filed Jul. 20, 2020, PCT No. PCT/US2020/042762 § 371(c)(1), (2) Date Jan. 18, 2022, PCT Pub. No. WO2021/011935, PCT Pub. Date Jan. 21, 2021.
Claims priority of provisional application 62/951,905, filed on Dec. 20, 2019.
Claims priority of provisional application 62/875,889, filed on Jul. 18, 2019.
Prior Publication US 2022/0257661 A1, Aug. 18, 2022
Int. Cl. A61K 35/28 (2015.01); A61K 31/05 (2006.01)

CPC A61K 35/28 (2013.01) [A61K 31/05 (2013.01)]

8 Claims

1. A composition comprising:

i) a mesenchymal stem cell (MSC) secretome preparation comprising MSC growth factors, MSC extracellular vesicles, MSC exosomes, and/or MSC extracts; and

ii) a cannabinoid;

wherein the MSC growth factors, MSC extracellular vesicles, MSC exosomes, and/or MSC extracts are obtained from human bone-marrow MSCs cultured under conditions comprising about 0.1% to about 5% oxygen and an acidic pH of 6.2 to 6.9.